Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study
European Journal of Cancer2020Vol. 141, pp. 171–184
Citations Over TimeTop 10% of 2020 papers
Karlijn de Joode, Daphne W. Dumoulin, Jolien Tol, Hans M. Westgeest, Laurens V. Beerepoot, Franchette W.P.J. van den Berkmortel, Pim Mutsaers, Nico G. J. van Diemen, Otto Visser, Esther Oomen‐de Hoop, Haiko J. Bloemendal, Hanneke W.M. van Laarhoven, Lizza Hendriks, John B.A.G. Haanen, Elisabeth G.E. de Vries, Anne‐Marie C. Dingemans, Astrid A.M. van der Veldt, C.J. van Loenhout, Cor H. van der Leest, Annemarie Becker‐Commissaris, Jessica S.W. Borgers, F. Terhegggen, Ben E.E.M. van den Borne, L.J.C. van Warmerdam, L. van Leeuwen, Femke S. van der Meer, M. Tiemessen, D.M. van Diepen, Yarne Klaver, A.P. Hamberg, Eduard J. Libourel, Luc J. A. Strobbe, Marissa Cloos, Erica J. Geraedts, Jan C. Drooger, Raban Heller, Jan Willem B. de Groot, Jos A. Stigt, Veerle J. Nuij, Cordula Pitz, Marije Slingerland, Frank J. Borm, Brigitte C.M. Haberkorn, Susan C. van ‘t Westeinde, Maureen J.B. Aarts, J.W.G. van Putten, Mina Youssef, Geert A. Cirkel, Gerarda J.M. Herder, C. R. van Rooijen, Emanuel Citgez, Nicole P. Barlo, Béatrice Scholtes, Rutger H.T. Koornstra, Niels Claessens, Laura M. Faber, C.H. Rikers, R.A.W. van de Wetering, Gerald Veurink, B.W. Bouter, Ilse Houtenbos, Mathieu Bard, Karin H. Herbschleb, Elisabeth A. Kastelijn, Pepijn Brocken, Gea Douma, Mathilde Jalving, T. Jeroen N. Hiltermann, Olga C.J. Schuurbiers-Siebers, Karijn P.M. Suijkerbuijk, Anne S. R. van Lindert, Agnès J. van de Wouw, Vivian E. M. van Kampen‐van den Boogaart, Sandra D. Bakker, E. Looysen, A.L. Peerdeman, Wouter K. de Jong, Ester Siemerink, Ada Staal, Bas Franken, Wouter H. van Geffen, Gerben Bootsma
Abstract
The findings in this registry indicate that patients with a haematological malignancy or lung cancer have an increased risk of a worse outcome of COVID-19. During the ongoing COVID-19 pandemic, these vulnerable patients should avoid exposure to severe acute respiratory syndrome coronavirus 2, whereas treatment adjustments and prioritising vaccination, when available, should also be considered.
Related Papers
- → And now for something completely different: from 2019-nCoV and COVID-19 to 2020-nMan(2020)27 cited
- → Realizing the Potential of Anti–SARS-CoV-2 Monoclonal Antibodies for COVID-19 Management(2022)21 cited
- → Confirmation of SARS-CoV-2 airborne dissemination indoors using “COVID-19 traps”(2021)4 cited
- → Fachinformationen zu SARS-CoV-2/COVID-19(2020)